These 3 Stocks Are Ripe for a Takeover
They’re among the mid-cap names I expect to attract significant buyout interest should the projected uptick in M&A activity arrive for the biotech space…
Read MoreAuthor: Bret Jensen, Biotech Gems
These Stocks Are Undervalued Right Now and Have Strong Upcoming Catalysts
If all goes well, over the next year they could be worth significantly more than what they currently trade for…
Read MoreI’ve Been Adding Incrementally to These Four Stocks on their Recent Decline
They’re selling for under $10 and have attractive risk to reward profiles…
Read MoreThese 3 Undervalued Stocks Should Do Well Regardless of Who Wins the Election
One is very cheap and has years of steady growth ahead of it…
Read More
These Four Stocks Could See Positive Catalysts in the Quarters Ahead
In addition, they could benefit from the increasingly positive investor view of the sector
Read More